Clinical Trials Logo

Rhinitis, Allergic, Seasonal clinical trials

View clinical trials related to Rhinitis, Allergic, Seasonal.

Filter by:

NCT ID: NCT00805584 Completed - Clinical trials for Rhinitis, Allergic, Seasonal

Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated With Aerius (Desloratadine)(P03442)

Start date: May 2003
Phase: Phase 4
Study type: Interventional

The purpose of this study was to test the effectiveness and side effects of desloratadine (Aerius) in patients with hayfever. Patients took desloratadine once a day for 15 days. At the end of therapy, they scored how severe their hayfever symptoms were and how they responded to therapy. Side effects were recorded.

NCT ID: NCT00805324 Completed - Asthma Clinical Trials

Study of the Effectiveness and Safety of Desloratadine (Aerius) Syrup in Children With Hayfever With or Without Asthma (P03472)

Start date: May 2003
Phase: Phase 3
Study type: Interventional

The purpose of this study was to test the effectiveness and safety of desloratadine (Aerius) syrup in children with hayfever with or without asthma. Patients took desloratadine syrup once a day for 28 days. Once a week, the doctor measured the patient's hayfever symptoms. The doctor also rated how much relief the patient got from treatment and recorded any side effects.

NCT ID: NCT00794846 Completed - Clinical trials for Seasonal Allergic Rhinitis

Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03180)

Start date: December 2002
Phase: Phase 4
Study type: Interventional

This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex® or Zyrtec®. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Zyrtec, the patient prefers more.

NCT ID: NCT00794768 Completed - Clinical trials for Seasonal Allergic Rhinitis

Preference for Clarinex Tablets vs Allegra Tablets in Patients With Seasonal Allergies (P03178)

Start date: November 2002
Phase: Phase 4
Study type: Interventional

This was a crossover study designed to see if patients with seasonal allergy symptoms preferred Clarinex® or Allegra®. Patients were randomized to take 7 days of Clarinex or Allegra treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Allegra, the patient prefers more.

NCT ID: NCT00794599 Completed - Clinical trials for Seasonal Allergic Rhinitis

Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182)

Start date: December 2002
Phase: Phase 4
Study type: Interventional

This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex® or Zyrtec®. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Zyrtec, the patient prefers more.

NCT ID: NCT00794495 Completed - Clinical trials for Seasonal Allergic Rhinitis

Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)

Start date: December 2002
Phase: Phase 4
Study type: Interventional

This was a crossover study designed to see if patients with allergy symptoms preferred Clarinex® or Zyrtec®. Patients were randomized to take 7 days of Clarinex or Zyrtec treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Zyrtec, the patient prefers more.

NCT ID: NCT00794248 Completed - Clinical trials for Seasonal Allergic Rhinitis

Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03179)

Start date: November 2002
Phase: Phase 4
Study type: Interventional

This was a crossover study designed to see if patients with seasonal allergy symptoms preferred Clarinex® or Allegra®. Patients were randomized to take 7 days of Clarinex or Allegra treatment, followed by a 5 to 28-day washout period (days when no drug is given), followed by 7 days of the opposite treatment. At the end of each 7-day treatment, patients were asked questions to determine which drug, Clarinex or Allegra, the patient prefers more.

NCT ID: NCT00790023 Completed - Clinical trials for Seasonal Allergic Rhinitis

Clinical Trial to Assess the Efficacy and Safety of Ciclesonide Hydrofluoroalkane (HFA) Nasal Aerosol for the Treatment of Seasonal Allergic Rhinitis

Start date: November 2008
Phase: Phase 3
Study type: Interventional

To demonstrate the efficacy of ciclesonide HFA applied as a nasal aerosol (160 μg and 80 μg) once daily compared to placebo in subjects with SAR.

NCT ID: NCT00784732 Completed - Clinical trials for Seasonal Allergic Rhinitis

A Study to Compare the Efficacy of QAV680 Against Placebo in Treating Seasonal Allergic Rhinitis in an Environmental Exposure Chamber

Start date: September 2008
Phase: Phase 2
Study type: Interventional

This study will compare the effectiveness of QAV680 against placebo in treating the symptoms of seasonal allergic rhinitis in an Environmental Exposure Chamber.

NCT ID: NCT00783211 Completed - Clinical trials for Seasonal Allergic Rhinitis

Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)

Start date: August 1, 2004
Phase: Phase 4
Study type: Interventional

This was a randomized, double-blind, parallel-group, multicenter study that used both an active control (fexofenadine) and a placebo control to evaluate desloratadine 5 mg once daily during a 15-day treatment period. The active treatments and placebo were allocated in a 2:2:1 ratio.